SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending amid heightened anticipation for the Senate Banking Committee's markup session on the Digital Asset Market Clarity Act, which investors hope will provide much-needed regulatory certainty. Community members are split between optimistic bulls expecting institutional adoption and skeptical traders frustrated by the asset's persistent volatility and history of failing to sustain breakout rallies.

Trulieve Cannabis Corp. engages in the provision of medical cannabis products and services. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis

Trulieve Cannabis is trending as the community scrutinizes the company's shift toward redomiciling to Delaware while navigating persistent tax headwinds and regulatory uncertainty surrounding federal rescheduling. Investors are actively debating the timing of potential tax relief and institutional support, weighing long-term sector growth against ongoing frustration over recent price volatility and unsuccessful efforts to secure adult-use ballot initiatives in Florida.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant (QNT) is attracting significant community attention as investors speculate on its role in institutional adoption, specifically noting its utility in bank tokenization pilots and regulatory compliance projects. Traders are actively discussing the potential for price appreciation fueled by the asset's limited supply, with many using recent market volatility as an opportunity to accumulate positions for long-term holding.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as investors digest a surge in institutional ownership, including significant stakes from major entities like Nvidia, fueling community debate over its pivot into AI infrastructure and optical networking. While short-term traders navigate volatility around key technical levels, long-term investors are actively discussing Nokias potential as a key player in the evolving AI-RAN and telecom landscape.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending due to the major announcement of its $17 billion acquisition of TopBuild, a strategic move that significantly expands its footprint as a leading building products distributor. Investors and community members are actively debating the long-term impact of this aggressive roll-up strategy, focusing on its potential to drive future revenue growth and market share while managing the implications of dilution.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is trending as market participants analyze broader economic risks, including geopolitical instability and shifts in trade policy, while weighing the performance of broad-market index funds against sector-specific volatility. The community remains focused on long-term wealth creation strategies, with ongoing debate over the impact of geopolitical escalations on energy costs and the relative stability of passive index investing in a fractured global environment.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. (EMAT) is capturing significant attention due to its focus on domestic critical mineral supply chains and a tightly held float that has triggered high-volatility price swings. Community members are actively debating the company's potential as a strategic metals play, with many closely tracking its recent strategic agreements and capacity scaling news as key indicators for its long-term momentum.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Dexcom Inc

Dexcom shares are trending following a strategic cooperation agreement with activist investor Elliott Management, which includes the appointment of new board members and an expanded share buyback program. While some investors are optimistic about the company's long-term pivot toward broader biosensing and governance improvements, the community remains divided, with active discussions focusing on technical price action, skepticism over management's ability to drive growth, and contrasting views on competitive pressures in the continuous glucose monitoring space.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune is currently trending as shareholders and analysts debate the impact of the FDA's second rejection of RP1, with community discourse divided between optimism for a potential regulatory reversal and concerns over the company's long-term financial viability. Traders are actively monitoring heightened volatility and high short interest, while discussions focus on the possibility of a leadership shift at the agency and the company's limited runway for future clinical development.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is experiencing a strong momentum rally as investors position for the company's potential role in addressing AI data center power constraints, a narrative bolstered by the broader fuel-cell sector's recent strength. The community is actively discussing heavy institutional accumulation, intense options call volume, and the anticipation of signed contracts from its data center proposal pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Trump said that the administration will release a full report on a Hantavirus on Friday.</li><li>The outbreak aboard the Dutch-flagged cruise ship Hondius has resulted in three deaths, six confirmed infections and additional suspected cases.</li><li>Moderna drew attention due to its hantavirus vaccine partnership with Korea University.</li></ul><p>Shares of vaccine makers and biodefense companies rallied overnight on&nbsp;Friday&nbsp;after U.S. President Donald Trump addressed a deadly hantavirus outbreak aboard a cruise ship and promised a full update on the situation.</p><p>Overnight,&nbsp;<a href="https://stocktwits.com/symbol/EBS">Emergent BioSolutions (EBS)</a> climbed 3%, while&nbsp;<a href="https://stocktwits.com/symbol/INO">Inovio Pharmaceuticals (INO)</a> and&nbsp;<a href="https://stocktwits.com/symbol/NVAX">Novavax (NVAX)</a> each gained 2% and&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna (MRNA)</a> rose 1%.</p><h2 class="st-heading-2"><strong>Trump Promises Full Hantavirus Report</strong></h2><p>Trump said late Thursday that the administration was closely studying the outbreak from the Dutch-flagged cruise ship Hondius, where three passengers have died and several others became infected. “It’s very much, we hope, under control,” Trump said, adding that a full report will be released on Friday.</p><p>The outbreak has triggered six confirmed infections and additional suspected cases aboard the vessel, which had 150 passengers onboard during an Atlantic voyage from Argentina toward Europe. Authorities are still investigating how the virus spread on board.</p><p>Singapore has already isolated two passengers from the ship due to concerns about possible exposure during the trip. The World Health Organization (WHO) also issued an alert on the outbreak, although officials said that the global risk remains low and that hantavirus is less transmissible than COVID-19 or influenza. The virus involved is said to be the Andes strain, one of the few hantavirus variants associated with limited human-to-human transmission.</p><h2 class="st-heading-2"><strong>Moderna Hantavirus Program Back In Focus</strong></h2><p>Moderna is viewed as one of the U.S. government’s key vaccine platforms for outbreaks. Since 2023, the company has worked with Korea University’s Vaccine Innovation Center on an mRNA-based hantavirus vaccine candidate, with preclinical studies earlier this year showing protection against hantavirus infection in mice.</p><p>In 2024, Moderna received a $176 million award backed by the Biomedical Advanced Research and Development Authority (BARDA) in 2024 for the development of mRNA-based pandemic influenza vaccines and outbreak preparedness programs. Moderna’s partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) is also in focus, which previously said mRNA could help shorten vaccine-development timelines to as little as 100 days during outbreaks.</p><h2 class="st-heading-2"><strong>Inovio: Direct Hantavirus Play</strong></h2><p>Inovio, meanwhile, has the clearest hantavirus link among the stocks rallying overnight. The company previously participated in several hantavirus DNA vaccine studies targeting Hantaan, Puumala and Andes hantavirus strains. One National Institute of Allergy and Infectious Diseases-backed study evaluated an Andes virus DNA vaccine to prevent hantavirus pulmonary syndrome, while another U.S. Army-supported study examined mixed hantavirus DNA vaccines.</p><p>While none of Inovio’s hantavirus vaccine programs produced a commercial product, the outbreak revived speculative interest in companies with prior hantavirus research.</p><h2 class="st-heading-2"><strong>NVAX, EBS In Outbreak Spotlight</strong></h2><p>Investors frequently rotate into Novavax during virus headlines due to the company’s vaccine-development platform and history of rapidly developing candidates for pathogens such as Ebola, MERS and Zika. The company’s protein-based nanoparticle platform and Matrix-M adjuvant tech can generate vaccine candidates against emerging infectious diseases, already used in marketed COVID-19 and malaria vaccines.&nbsp;</p><p>Emergent BioSolutions, on the other hand, is often viewed as one of the U.S. government’s primary biodefense and medical-countermeasure contractors during public-health emergencies. The company has existing relationships with BARDA and makes products based on Anthrax, Ebola, smallpox, mpox and viral hemorrhagic fevers. Emergent previously received BARDA task orders for viral hemorrhagic fever therapeutics and has also participated in manufacturing efforts during outbreaks, including Ebola and Zika.</p><h2 class="st-heading-2"><strong>How Do Retail Traders Feel About INO, MRNA, NVAX, EBS?</strong></h2><p>On Stocktwits, retail sentiment for INO and NVAX was ‘extremely bullish’ amid ‘extremely high’ message volume, while MRNA saw ‘bullish’ sentiment with ‘high’ message volume. EBS also recorded ‘extremely bullish’ sentiment, though message volume remained ‘normal.’&nbsp;</p><p>Over the past year, MRNA has surged 102%, followed by EBS up 93% and NVAX higher by 55%, while INO has declined 22%.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-deutsche-bank-stake-boost-ahead-of-earnings/cZX2EhiReXG">SLS Stock Heads For Weekly Win: Deutsche Bank’s Stake Boost Draws Attention Ahead Of Q1 Earnings&nbsp;</a></p>

Trump holds a press conference announcing U.S. Vice President Mike Pence to lead the effort combating the spread of the coronavirus on February 26, 2020. (Photo by Yasin Ozturk/Anadolu Agency via Getty Images)

INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally

Inovio is the most direct hantavirus play based on earlier DNA vaccine studies targeting Andes, Hantaan, and Puumala strains.

Equity

Donald Degolyer Sells 15,481 Shares of Emergent Biosolutions (NYSE:EBS) Stock

Emergent Biosolutions Inc. (NYSE:EBS - Get Free Report) Director Donald Degolyer sold 15,481 shares of the company's stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $8.40, for a total transaction of $130,040.40. Following the completion of the transaction...

Insider Selling: Emergent Biosolutions (NYSE:EBS) Director Sells 17,202 Shares of Stock

Emergent Biosolutions Inc. (NYSE:EBS - Get Free Report) Director Kathryn Zoon sold 17,202 shares of the company's stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $8.40, for a total transaction of $144,496.80. Following the completion of the sale, the...

Keith Katkin Sells 15,481 Shares of Emergent Biosolutions (NYSE:EBS) Stock

Emergent Biosolutions Inc. (NYSE:EBS - Get Free Report) Director Keith Katkin sold 15,481 shares of the firm's stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $8.28, for a total transaction of $128,182.68. Following the transaction, the...

Emergent Biosolutions (NYSE:EBS) Director Sujata Tyagi Dayal Sells 13,761 Shares

Emergent Biosolutions Inc. (NYSE:EBS - Get Free Report) Director Sujata Tyagi Dayal sold 13,761 shares of the firm's stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $8.40, for a total transaction of $115,592.40. Following the completion of the transaction...

Emergent BioSolutions Shares Turnaround Update at 2026 Annual Meeting; All Proposals Approved

Emergent Biosolutions (NYSE:EBS) on Tuesday held its 2026 Annual Meeting of Stockholders, where shareholders voted on director elections, auditor ratification, executive compensation, and an...

Emergent Biosolutions (NYSE:EBS) Posts Quarterly Earnings Results, Beats Expectations By $0.46 EPS

Emergent Biosolutions (NYSE:EBS - Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, beating...

Emergent BioSolutions Q1 2026 Earnings Call: Complete Transcript

Q1 Earnings Estimate for EBS Issued By Benchmark

Emergent Biosolutions Inc. (NYSE:EBS - Free Report) - Stock analysts at Benchmark issued their Q1 2026 earnings per share estimates for Emergent Biosolutions in a research report issued on Tuesday...

Emergent Biosolutions (EBS) Expected to Announce Quarterly Earnings on Thursday

Emergent Biosolutions (NYSE:EBS) will be releasing its Q1 2026 earnings after the market closes on Thursday, April 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-30-emergent-biosolutions-inc-stock...

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.09	--	--	N/A
Q1 '26	-$0.25	$0.21	184.00%	BEAT
Q4 '25	$0.11	-$0.43	-490.91%	MISSED
Q3 '25	-$0.07	$1.06	1689.99%	BEAT
Q2 '25	-$0.41	$0.16	138.71%	BEAT

EBS
Emergent Biosolutions Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest EBS News

EBSEmergent Biosolutions Inc